TY - JOUR
T1 - EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update
T2 - Treatment of Relapsing and Metastatic Prostate Cancer
AU - Tilki, Derya
AU - van den Bergh, Roderick C.N.
AU - Briers, Erik
AU - Van den Broeck, Thomas
AU - Brunckhorst, Oliver
AU - Darraugh, Julie
AU - Eberli, Daniel
AU - De Meerleer, Gert
AU - De Santis, Maria
AU - Farolfi, Andrea
AU - Gandaglia, Giorgio
AU - Gillessen, Silke
AU - Grivas, Nikolaos
AU - Henry, Ann M.
AU - Lardas, Michael
AU - J.L.H. van Leenders, Geert
AU - Liew, Matthew
AU - Linares Espinos, Estefania
AU - Oldenburg, Jan
AU - van Oort, Inge M.
AU - Oprea-Lager, Daniela E.
AU - Ploussard, Guillaume
AU - Roberts, Matthew J.
AU - Rouvière, Olivier
AU - Schoots, Ivo G.
AU - Schouten, Natasha
AU - Smith, Emma J.
AU - Stranne, Johan
AU - Wiegel, Thomas
AU - Willemse, Peter Paul M.
AU - Cornford, Philip
N1 - Publisher Copyright:
© 2024
PY - 2024/8
Y1 - 2024/8
N2 - Background and objective: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines. Methods: The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence. Key findings and limitations: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor–targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen–based therapy have become available for men with metastatic PCa. Conclusions and clinical implications: Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/). Patient summary: This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.
AB - Background and objective: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines. Methods: The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence. Key findings and limitations: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor–targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen–based therapy have become available for men with metastatic PCa. Conclusions and clinical implications: Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/). Patient summary: This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.
UR - http://www.scopus.com/inward/record.url?scp=85191876703&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2024.04.010
DO - 10.1016/j.eururo.2024.04.010
M3 - Review article
C2 - 38688773
AN - SCOPUS:85191876703
SN - 0302-2838
VL - 86
SP - 164
EP - 182
JO - European Urology
JF - European Urology
IS - 2
ER -
